Entrada Therapeutics Q4 GAAP EPS $(0.29) Misses $(0.17) Estimate, Sales $41.85M Beat $23.69M Estimate
Portfolio Pulse from Benzinga Newsdesk
Entrada Therapeutics (TRDA) reported a Q4 GAAP EPS of $(0.29), missing the $(0.17) estimate, but sales of $41.85M exceeded the $23.69M estimate. The EPS loss improved by 63.29% from the previous year, while sales significantly outperformed expectations.
March 13, 2024 | 11:21 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Entrada Therapeutics reported a Q4 GAAP EPS loss of $(0.29), missing estimates, but sales of $41.85M exceeded expectations, showing significant improvement in performance.
While the EPS miss might concern some investors, the significant beat on sales and the improvement in EPS loss from the previous year could be seen as positive indicators of the company's growth and operational efficiency. The mixed results make the short-term impact on the stock price uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100